Raman Spectroscopy Detection of Cell Surface Integrin on Monocytes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current laboratory screening tests for atherosclerosis and myocardial infarction primarily focus on lipid profiles, neglecting the role of monocyte activation and integrin expression, which are crucial in the inflammatory pathogenesis of atherosclerosis, leading to inadequate prediction of cardiovascular risk.
Innovation Solution
A method using Raman spectroscopy to detect and quantify cell surface integrin levels on monocytes by isolating them from a blood sample, adhering them to a spectroscopic support, illuminating with near-infrared light, and analyzing Raman spectra before and after binding with anti-integrin nanoparticles, to determine the severity of atherosclerosis and predict myocardial infarction risk.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current laboratory screening tests focus only on lipid profiles, then the testing procedure is simple and widely applicable, but the prediction accuracy of cardiovascular risk is insufficient
Solution Approach 1:
The patent combines Raman spectroscopy technology with traditional lipid profile testing to create a comprehensive cardiovascular risk assessment system. This merging allows the detection of both lipid levels and monocyte activation status (integrin expression) in a single integrated testing platform, thereby improving prediction accuracy while maintaining procedural simplicity through automation
Solution Approach 2:
The patent introduces Raman spectroscopy as an intermediary detection method that can non-invasively and rapidly assess monocyte activation status. This intermediary technology bridges the gap between simple blood sampling and complex cellular analysis, enabling accurate risk prediction without requiring sophisticated cell isolation and analysis procedures
2Measurement precision
If Raman spectroscopy with nanoparticle binding is used to detect integrin levels, then the detection sensitivity is significantly improved, but the measurement and detection difficulty increases
Solution Approach 1:
The patent utilizes changes in Raman spectral parameters (intensity, frequency shifts) before and after nanoparticle binding to quantify integrin levels. By monitoring specific spectral parameter changes rather than attempting direct molecular visualization, the method achieves high detection sensitivity while keeping the measurement process manageable through automated spectral analysis algorithms
Solution Approach 2:
The patent uses Raman spectroscopy to create a spectral 'copy' or fingerprint of the monocyte surface characteristics. This spectral copying approach allows indirect detection of integrin expression patterns without requiring direct physical manipulation or complex imaging of the cells, thereby maintaining measurement simplicity while achieving high sensitivity
Data Source
AI summary
Cell surface Raman spectroscopy and a quantitative measure of cell surface integrin from monocytes isolated from peripheral blood provide a measure of active inflammation. Patients with elevated lipid profiles and inflammatory status are at high risk for plaque producing atherosclerosis and candidates for aggressive treatment and clinical follow-up.